## JNJ: Johnson & Johnson - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.0% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($200.92)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 3, Bearish: 5)

**1. Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025**
- Source: ts2.tech | 20251226T000834 | Somewhat-Bearish | Relevance: 100%
- This article provides a comprehensive overview of key factors influencing Johnson & Johnson (JNJ) stock before the market open on December 26, 2025. It highlights recent talc litigation verdicts, ongoing portfolio reshaping plans including the DePuy Synthes separation, product and pipeline updates, and the impact of Washington's drug pricing pressure. Investors should monitor these elements as they navigate JNJ's defensive-stock appeal amid headline risks.

**2. Baltimore jury issues $1.5B verdict against Johnson & Johnson in baby powder case**
- Source: The Baltimore Banner | 20251224T200813 | Bearish | Relevance: 100%
- A Baltimore jury has awarded over $1.5 billion to Cherie Craft, who developed malignant peritoneal mesothelioma, an incurable form of cancer, as a result of using Johnson & Johnson's talc-based baby powder. The verdict includes $59.84 million for medical expenses, lost wages, and pain and suffering, along with $1.5 billion in punitive damages against Johnson & Johnson and Pecos River Talc for exposing Craft to asbestos. Johnson & Johnson has announced it will appeal the "egregious and patently unconstitutional verdict," while legal experts anticipate potential settlement negotiations.

**3. Johnson & Johnson (NYSE:JNJ) Receives Consensus Recommendation of "Moderate Buy" from Brokerages**
- Source: MarketBeat | 20251228T070826 | Bullish | Relevance: 100%
- Johnson & Johnson (NYSE:JNJ) has received a consensus "Moderate Buy" rating from 27 brokerages, with an average 1-year target price of $210.25. Institutional investors have significantly increased their holdings, with Norges Bank and Laurel Wealth Advisors making substantial new or increased investments. The company maintains a strong financial position with a market cap of $500.02 billion, a P/E ratio of 20.03, and pays a quarterly dividend of $1.30 per share.

**4. Johnson & Johnson will appeal talcum powder ruling**
- Source: CBS News | 20251226T223017 | Bearish | Relevance: 100%
- Johnson & Johnson plans to appeal a ruling that ordered the company to pay $1.5 billion to a woman. The woman alleged that decades of exposure to Johnson & Johnson's talcum powder caused her cancer.

**5. J&J eczema therapy fails in mid-stage trial (JNJ:NYSE)**
- Source: Seeking Alpha | 20251226T133152 | Bearish | Relevance: 100%
- Johnson & Johnson's experimental eczema therapy, JNJ-95475939 (JNJ-5939), faced a setback in a mid-stage trial, leading to a dip in the company's stock in premarket trading. The trial's results for the atopic dermatitis treatment did not meet expectations, impacting investor confidence.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Goldman Sachs | $240 | $213 | +13% |
| 2025-12-15 | B of A Securiti | $220 | $204 | +8% |
| 2025-12-12 | Morgan Stanley | $197 | $190 | +4% |
| 2025-12-11 | Citigroup | $232 | $215 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Goldman Sachs | main | Buy |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($3.81M) |
| Sells | 6 ($0.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.2%)
- Blackrock Inc.: 8.6% (+1.7%)
- State Street Corpora: 5.5% (-0.4%)
- JPMORGAN CHASE & CO: 4.9% (+109.0%)
- Geode Capital Manage: 2.3% (-7.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Forward P/E 18.0x stretched relative to 6% growth. Quality metrics strong (ROE 34%, margin 27%). Balance sheet: $8.4B free cash flow. Analyst sentiment positive (7 raises, avg +9%). Insider buying signal ($3.8M), management confidence. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $500.2B |
| Beta | 0.35 |
| 52W Range | $140.68 - $215.19 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.0 |
| Current P/E | 19.1 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.9% to -2.0% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.67), momentum weakening. RSI neutral at 57. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.02% (CS: 23) | Weak |
| RSI_14 | 56.7 | Neutral |
| MACD Histogram | -0.67 | Bearish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.043x | Above |
| vs SMA200 | 1.198x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $207.64
- **Stop Loss:** $200.92 (3.2% risk)
- **Target:** $214.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 196
- **Position Value:** $40,697.44
- **Portfolio %:** 40.70%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-21 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.76 | $2.80 | +1.5% |
| 2025Q2 | $2.68 | $2.77 | +3.2% |
| 2025Q1 | $2.58 | $2.77 | +7.4% |
| 2024Q4 | $2.01 | $2.04 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*